Nearly four months after investors learned the FDA wanted more clinical data on Dyax Corp.'s hereditary angioedema drug DX-88, the agency recommended that the company complete a confirmatory Phase III trial to validate its patient reported outcome measure. (BioWorld Today)
Corcept Therapeutics Inc.'s antipsychotic drug, Corlux, failed in its first Phase III trial, devastating the company's stock, which lost more than half of its value. (BioWorld Today)
In a worldwide multi-target alliance focused on treatments for inflammatory disorders, ChemoCentryx Inc. signed a deal potentially worth $1.5 billion with GlaxoSmithKline plc. (BioWorld Today)
In one of the largest European private placements conducted this year, Ablynx NV raised €40 million (US$51.2 million) in a Series C round to drive more of its programs into preclinical and clinical development. (BioWorld Today)
